Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer

February 29, 2024

The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies for HER2-negative metastatic breast cancer including immunotherapy, targeted therapy, and antibody-drug conjugates. The treatment landscape of metastatic breast cancer is evolving constantly. The decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence for selection of optimal therapy and a detailed discussion of the benefits and risks associated with all possible treatment strategies with patients. With expanding treatment options, clinicians should understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. It is important for clinicians to stay up-to-date with the available treatment options to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

Target Audience

This activity is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR- and HER2- receptor status.
  • Assess the safety profile of agents used in management of metastatic HR-positive and HER2-negative metastatic breast cancer and outline strategies to optimally manage common toxicities. 
  • Outline new and emerging therapeutic options for patients with metastatic breast cancer.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, GSK, Lantheus, and Novartis. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
01/09/2024
Course expires: 
05/05/2024
Event starts: 
02/29/2024 - 11:00am EST
Event ends: 
02/29/2024 - 12:00pm EST
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Add to calendar: 

D. Hunter Boggs, MD
O'Neal Comprehensive Cancer Center at UAB

Erica M. Stringer-Reasor, MD
O'Neal Comprehensive Cancer Center at UAB

Claire Rummage, PharmD, BCOP
O'Neal Comprehensive Cancer Center at UAB

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Claire Rummage, PharmD, BCOP

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Erica M. Stringer-Reasor, MD
ASCO: Honoraria
AstraZeneca Pharmaceuticals LP: Consulting Fee
BMS-AACR Workshop: Honoraria
Eli Lilly and Company: Consulting Fee
Merck & Co., Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
OncLive: Honoraria
SeaGen: Consulting Fee

D. Hunter Boggs, MD
Varian Medical Systems, Inc.: Grant/Research Support

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-015-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00058303; Approval #: 240000375

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Thursday, February 29, 2024, from 11:00 AM – 12:00 PM EST (UTC -5).
The recorded activity is available here.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing